Table 3.
Comparison of Treatment, Laboratory and Spirometry Results Between Groups
| Parameters | Group | P value | ||
|---|---|---|---|---|
| ACO (n=17) | COPD (n=17) | Asthma (n=33) | ||
| OCSs | 3 (17.65%) | 2 (11.76%) | 18 (54.55%) | p=0.003 * Asthma>COPD |
| ICSs | 17 (100.00%) | 7 (41.18%) | 33 (100.00%) | p<0.001 * ACO, Asthma>COPD |
| ICSs dose (fluticasone propionate) [µg], median (IQR) | 400 (320–1400) | 400 (360–860) | 1000 (800–1920) | p=0.01 * Asthma>ACO, COPD |
| LABAs | 17 (100.00%) | 15 (88.24%) | 33 (100.00%) | p=0.123 |
| LAMAs | 12 (70.59%) | 14 (82.35%) | 8 (24.24%) | p<0.001 * COPD, ACO>Asthma |
| A history of atopy | 5 (29.41%) | 0 (0.00%) | 15 (45.45%) ** | p=0.003 * Asthma, ACO>COPD |
| Total IgE ≥ 100 IU/mL | 8 (47.06%) | 2 (11.76%) | 18 (54.55%) | p=0.013 * Asthma, ACO>COPD |
| Absolute eosinophil count [cells/µL], median (IQR) | 170 (60–580) | 200 (130–320) | 190 (100–380) | p=0.995 |
| Percentage of eosinophils in blood [%], median (IQR) | 1.8 (0.9–7.5) | 2.6 (1.2–4.15) | 3.5 (1.4–5.2) | p=0.85 |
| FEV1/FVC [%], median (IQR) | 57.7 (53.07–61.24) | 47.08 (42.84–56.92) | 64.12 (55.14–73.2) | p<0.001 * Asthma>ACO,COPD |
| FEV1 [l], median (IQR) | 1.48 (1.16–2.04) | 1.03 (0.85–1.12) | 1.98 (1.48–2.25) | p<0.001 * Asthma, ACO> COPD |
| FEV1 [%],median (IQR) | 62.1 (50.95–74.45) | 44.7 (33.6–53.07) | 68 (54.2–79.45) | p=0.002 * Asthma, ACO> COPD |
| FEV1/FVC [%] after SABA, median (IQR) | 59.28 (57.42–61.13) | 51.52 (44.88–58.28) | 68.62 (62.29–76.24) | p<0.001 * Asthma>ACO, COPD |
| FEV1 after SABA [l], median (IQR) | 1.71 (1.46–2.13) | 1.13 (1.02–1.51) | 2.17 (1.8–2.69) | p<0.001 * Asthma, ACO> COPD |
| FEV1 after SABA [%], median (IQR) | 68.34 (57–78.7) | 51 (35–57.6) | 80.7 (55.7–92) | p=0.01 * Asthma, ACO> COPD |
Notes: Data is presented as median (IQR) for continuous variables and count (%) for categorical variables. *Statistically significant (p<0,05). **Missing data for 1 patient.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; OCSs, oral corticosteroids; ICSs, inhaled corticosteroids; LABAs, long-acting β2-agonists; LAMAs, long-acting muscarinic antagonists; IgE, immunoglobulin E; SABA, short-acting β2-agonist.